Skip to content

REVIVA PHARMACEUTICALS HOLDINGS, INC.

NASDAQ: RVPH

Company: Reviva Pharmaceuticals Holdings, Inc.
Ticker: Nasdaq: RVPH
Sector: Healthcare
Investor Contact: Ben Shamsian

Reviva Pharmaceuticals Holdings, Inc. Financials

Financials – Current & Historical

CONSOLIDATED BALANCE SHEETS
v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Assets    
Cash and cash equivalents $ 13,476,331 $ 23,367,456
Prepaid clinical trial costs 540,601 78,295
Prepaid expenses and other current assets 666,435 254,637
Total current assets 14,683,367 23,700,388
Non-current prepaid clinical trial costs 819,721 0
Total Assets 15,503,088 23,700,388
Liabilities    
Short-term debt 458,154 0
Accounts payable 6,283,430 3,849,108
Accrued clinical expenses 6,723,719 11,966,812
Accrued compensation 635,587 958,607
Other accrued liabilities 500,616 400,490
Total current liabilities 14,601,506 17,175,017
Warrant liabilities 89,010 806,655
Total Liabilities 14,690,516 17,981,672
Commitments and Contingencies  
Stockholders' Equity    
Common stock, par value of $0.0001; 315,000,000 shares authorized; 46,579,199 and 27,918,560 shares issued and outstanding as of December 31, 2024 and 2023, respectively 4,658 2,792
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2024 and 2023 0 0
Additional paid-in capital 165,080,964 140,070,172
Accumulated deficit (164,273,050) (134,354,248)
Total stockholders' equity 812,572 5,718,716
Total Liabilities and Stockholders' Equity $ 15,503,088 $ 23,700,388
CONSOLIDATED STATEMENTS OF INCOME
v3.25.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses    
Research and development $ 22,907,368 $ 31,419,817
General and administrative 7,891,521 8,083,819
Total operating expenses 30,798,889 39,503,636
Loss from operations (30,798,889) (39,503,636)
Other income (expense)    
Gain (loss) on remeasurement of warrant liabilities 717,645 (239,216)
Interest expense (18,497) (33,725)
Interest income 361,369 398,413
Other (expense) income, net (160,916) 134,276
Total other income, net 899,601 259,748
Loss before provision for income taxes (29,899,288) (39,243,888)
Provision for income taxes 19,514 16,949
Net loss $ (29,918,802) $ (39,260,837)
Net loss per share:    
Basic and diluted (in dollars per share) $ (0.9) $ (1.65)
Weighted average shares outstanding    
Basic and diluted (in shares) 33,147,424 23,798,203
CONSOLIDATED STATEMENTS OF CASH FLOWS
v3.25.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities    
Net loss $ (29,918,802) $ (39,260,837)
Adjustments to reconcile net loss to net cash used in operating activities    
Change in fair value of warrant liabilities (717,645) 239,216
Stock-based compensation expense 1,630,341 3,413,354
Changes in operating assets and liabilities:    
Prepaid clinical trial costs (current and non-current) (1,282,027) 186,288
Prepaid expenses and other current assets (411,798) (115,401)
Accounts payable 2,291,186 328,837
Accrued expenses and other current liabilities (5,135,171) 6,884,190
Net cash used in operating activities (33,543,916) (28,324,353)
Cash flows from financing activities    
Proceeds from issuance of short-term debt 976,904 667,500
Repayment of short-term debt (518,750) (667,500)
Proceeds from issuance of common stock, common stock warrants, prefunded warrants and from modification of existing warrants, in offerings, net of issuance costs 23,194,488 27,494,103
Proceeds from exercise of warrants 149 5,677,850
Net cash provided by financing activities 23,652,791 33,171,953
Net (decrease) increase in cash and cash equivalents (9,891,125) 4,847,600
Cash and cash equivalents, beginning of period 23,367,456 18,519,856
Cash and cash equivalents, end of period 13,476,331 23,367,456
Supplemental disclosures of cash flow information:    
Cash paid for taxes 3,417 19,754
Cash paid for interest 18,497 30,622
Noncash Investing and Financing Activities:    
Settlement of bonuses in form of stock options 330,816 0
Warrant modification recorded in stockholders' equity 1,073,416 0
Transaction costs related to offering included in accounts payable 143,136 0
Common Stock Warrants [Member]    
Noncash Investing and Financing Activities:    
Issuance of warrants 10,421,225 0
Prefunded Warrants [Member]    
Noncash Investing and Financing Activities:    
Issuance of warrants 470,057 0
Underwriter Warrants [Member]    
Noncash Investing and Financing Activities:    
Issuance of warrants $ 165,952 $ 0

Arrow